Preventive Care


Elective services to optimise your preventive care:

Ultrasound of the uterus and ovaries
A vaginal ultrasound can allow early detection of changes to the uterine lining and non-palpable growths of the ovaries and uterus in the lesser pelvis.
We recommend this examination annually.

Ultrasound of the mammary glands
Unfortunately, lumps in the breast tissue are not always noticeable to the touch but can often be detected by an ultrasound.
We recommend this examination annually.
Of course, none of these examinations provide 100 % certainty and they also cannot prevent breast cancer or ovarian cancer. However, modern ultrasound technology can also detect small lumps which are not yet noticeable to the touch, making an early diagnosis possible.

IUD position check
Any foreign object inside the body should regularly be checked to ensure it is positioned correctly, as firstly this influences the effectiveness of the birth control and secondly it prevents damage to other organs.

HPV test
Using the pap smear tests for the human papillomavirus (HPV), 95% of early stages of all cervical cancers are detected. If the results are good, it is recommended that you repeat the HPV test every three years.

ThinPrep
The monolayer cervical smear, also referred to as cervical cytology, is a clear advancement of the PAP smear, which has now been used for 50 years: with a PAP smear only about 20% of the cells end up on the specimen holder, whilst 80% are left on the brush, unanalysed. With cervical cytology, special collection and preservation methods enable virtually all of the collected cells to be examined.
This smear test is recommended from 20 years of age.

Immunological stool test
A simple and reliable enzyme rapid test for semiquantitative detection of M2-PK. M2-PK was identified as the key enzyme of polyps and colon cancer cells. The test results are available within minutes. Only a small stool sample is required for this test. This test is recommended annually, starting at the latest at 40 years of age. This test is not part of the cancer screening guidelines.  www.genogyn.de

Bladder cancer test
Each year almost 30,000 people are diagnosed with bladder cancer. The earlier it is diagnosed, the better the survival rate. The NMP22 bladder check rapid test is a simple urine test which checks for the tumour marker NMP22. This test is the only FDA-approved screening and monitoring test and it offers a very high sensitivity to detect bladder carcinomas, particularly in the early stages. This screening provides the physician and patient with a simple, low-cost option to diagnose bladder cancer, in many cases in the early stages. This test is not part of the cancer screening guidelines.  www.genogyn.de